Scientific article

An update on actively targeted liposomes in advanced drug delivery to glioma

Published inInternational journal of pharmaceutics, vol. 602, 120645
Publication date2021-06-01
First online date2021-04-27

High-grade glioma is one of the most aggressive types of cancer with a low survival rate ranging from 12 to 15 months after the first diagnosis. Though being the most common strategy for glioma therapy, conventional chemotherapy suffers providing the therapeutic dosage of common therapeutics mostly because of limited permeability of blood-brain barrier (BBB), and blood-brain tumor barrier (BBTB) to anticancer agents. Among various nanoformulations, liposomes are considered as the most popular carriers aimed for glioma therapy. However, non-targeted liposomes which passively accumulate in most of the cancer tissues mainly through the enhanced permeation and retention effect (EPR), may not be applicable for glioma therapy due to BBB tight junctions. In the recent decade, the surface modification of liposomes with different active targeting ligands has shown promising results by getting different chemotherapeutics across the BBB and BBTB and leading them into the glioma cells. The present review discusses the major barriers for drug delivery systems to glioma, elaborates the existing mechanisms for liposomes to traverse across the BBB, and explores the main strategies for incorporation of targeting ligands onto the liposomes. It subsequently investigates the most recent and relevant studies of actively targeted liposomes modified with antibodies, aptamers, monosaccharides, polysaccharides, proteins, and peptides applied for effective glioma therapy, and highlights the common challenges facing this area. Finally, the actively targeted liposomes undergoing preclinical and clinical studies for delivery of different anticancer agents to glioma cells will be reviewed.

  • Active targeting
  • Blood-brain barrier
  • Brain cancer
  • Drug delivery
  • Glioma
  • Liposome
  • Blood-Brain Barrier
  • Brain Neoplasms / drug therapy
  • Cell Line, Tumor
  • Drug Delivery Systems
  • Glioma / drug therapy
  • Humans
  • Liposomes
Citation (ISO format)
MOJARAD-JABALI, Solmaz et al. An update on actively targeted liposomes in advanced drug delivery to glioma. In: International journal of pharmaceutics, 2021, vol. 602, p. 120645. doi: 10.1016/j.ijpharm.2021.120645
Main files (1)
Article (Published version)
ISSN of the journal0378-5173

Technical informations

Creation03/01/2022 11:11:00 AM
First validation03/01/2022 11:11:00 AM
Update time03/16/2023 7:28:45 AM
Status update03/16/2023 7:28:43 AM
Last indexation02/12/2024 12:25:19 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack